A drugmaker's popular new shingles vaccine faces shortages due to high demand (GSK)
Shingrix, a new shingles vaccine by drugmaker GlaxoSmithKline, was approved for use by the FDA in 2017. It is currently experiencing shortages due to high demands. Shingrix is significantly more effective than Zostavax, which was the shingles vaccine that has been used since 2006.
Shipments of a new shingles vaccine by GlaxoSmithKline are flying off the shelves within days of being delivered. The popularity of the vaccine, called Shingrix, caught the drugmaker by surprise, and it underestimated the amount that it needed to make which resulted in a slight lag in production.
The CDC announced in June that the unexpectedly high demand of Shingrix had prompted GSK to impose order limits that have resulted in spotty availability in pharmacies, clinics and hospitals.
JOIN OUR PULSE COMMUNITY!
Eyewitness? Submit your stories now via social or: